News | Contrast Media | September 12, 2017

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

Medical Imaging Drugs Advisory Committee (MIDAC) votes 13 to 1 to add warning of the possible risks of gadolinium retention

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

September 12, 2017 — The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly last week to recommend new labels on gadolinium-based contrast agents (GBCAs) warning of the possibility of gadolinium retention in the body following administration during magnetic resonance imaging (MRI) exams. The labels will further explain that linear GBCAs carry a greater risk than macrocyclic agents, and that there is a greater risk for certain patient populations, according to Medscape.

The meeting, held Sept. 8, brought FDA officials together with healthcare professionals, industry representatives, patients and patient advocacy groups to discuss the merit of changing the regulatory approach for GBCAs. Representatives from Guerbet, Bayer, Bracco and GE Healthcare were all present at the meeting.

Concerns have emerged about gadolinium-based contrast agents in recent years as research has suggested that gadolinium is retained in the body, particularly in the brain, after administration and could cause adverse health effects, particularly for patients with renal failure. The FDA issued a Drug Safety Communication in May 2017 titled “No Harmful Effects Identified With Brain Retention,” in which the agency said it had not identified any adverse health effects from gadolinium retained in the brain, but that it would continue its review. 

In a statement released before the Sept. 8 meeting, the FDA said, “FDA’s approach has been educational: alerting the public and clinicians to the retention phenomenon but not issuing any restrictions on use because toxic effects in humans have not been established.”

For more information: www.fda.gov

 

Related Content on MRI Gadolinium Retention in the Brain

FDA: No Harm in MRI Gadolinium Retention in the Brain

Recent Trends and Developments in Contrast Media

VIDEO: MRI Gadolinium Contrast Retention in the Brain

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

Related Content

New Module Creates a Warped MRI Scan that Matches Real-Time Ultrasound Results (Graphic: Business Wire)

New Module Creates a Warped MRI Scan that Matches Real-Time Ultrasound Results (Graphic: Business Wire)

News | Artificial Intelligence | May 07, 2021
3D aMRI not only provides a stunning look inside the "beating brain", but it can also measure this physiological motion in all directions. Here, the amplitude of brain motion is overlayed for each brain slice and orientation in 3D. Image credit: 3D aMRI method outlined in Abderezaei et al. Brain Multiphysics (2021); Terem et al. Magnetic Resonance in Medicine (2021).

3D aMRI not only provides a stunning look inside the "beating brain", but it can also measure this physiological motion in all directions. Here, the amplitude of brain motion is overlayed for each brain slice and orientation in 3D. Image credit: 3D aMRI method outlined in Abderezaei et al. Brain Multiphysics (2021); Terem et al. Magnetic Resonance in Medicine (2021).

News | Magnetic Resonance Imaging (MRI) | May 06, 2021
May 6, 2021 — Magnetic Resonance Imaging
After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
The contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement

image courtesy of Guerbet

News | Contrast Media | May 03, 2021
Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or
News | Artificial Intelligence | April 30, 2021
April 30, 2021 — Canon Medical is bringing the power of accessible...
The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | April 30, 2021
April 30, 2021 — In almost 10 percent of...
Using ultra-high field magnetic resonance imaging (MRI) to map the brains of people with #Down_syndrome (#DS), #researchers from #CaseWesternReserveUniversity, #ClevelandClinic, University Hospitals and other institutions detected subtle differences in the structure and function of the #hippocampus—a region of the #brain tied to memory and learning.

Using ultra-high field magnetic resonance imaging (MRI) to map the brains of people with Down syndrome (DS), researchers from Case Western Reserve University, Cleveland Clinic, University Hospitals and other institutions detected subtle differences in the structure and function of the hippocampus—a region of the brain tied to memory and learning.

News | Magnetic Resonance Imaging (MRI) | April 29, 2021
April 29, 2021 — Using...
Examples of axial FLAIR sequences from studies within dataset A. From left to right: a patient with a 'likely normal' brain; a patient presenting an intraparenchymal hemorrhage within the right temporal lobe; a patient presenting an acute infarct of the inferior division of the right middle cerebral artery; and a patient with known neurocysticercosis presenting a rounded cystic lesion in the left middle frontal gyrus. Image courtesy of Radiological Society of North America

Examples of axial FLAIR sequences from studies within dataset A. From left to right: a patient with a 'likely normal' brain; a patient presenting an intraparenchymal hemorrhage within the right temporal lobe; a patient presenting an acute infarct of the inferior division of the right middle cerebral artery; and a patient with known neurocysticercosis presenting a rounded cystic lesion in the left middle frontal gyrus. Image courtesy of Radiological Society of North America

News | Artificial Intelligence | April 22, 2021
April 22, 2021 — An artificial intellige...
pediatric MRI brain imaging in children

Getty Images

News | Pediatric Imaging | March 25, 2021
March 25, 2021 — A large study of brain magnetic reso...